17 March 2023 - Prestige Biopharma said on Thursday that its new pancreatic cancer antibody drug candidate, PBP1510, (ulenistamab), was granted FDA fast track designation.
PBP1510 was also designated as an orphan drug by three regulators in 2020 including the FDA, the EMA and the MFDS in Korea.